SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for scientific trials, right this moment introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm growing therapies for neurodegenerative illnesses. The outcomes had been shared on the 2025 Alzheimer’s & Parkinson’s Drug Improvement Summit in Boston.
The collaboration centered on remynd’s Section 2a scientific trial of REM127, an investigational, first-generation small molecule remedy focusing on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The research enrolled a restricted variety of individuals and measured modifications in AD biomarkers over a brief remedy window.
Unlearn supported the research by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin skilled on knowledge from greater than 26,000 individuals throughout landmark AD datasets resembling ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their scientific and biomarker trajectories below customary care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering an extra layer of proof to assist interpret modifications noticed within the handled inhabitants. This method is especially priceless in early-phase research the place small pattern sizes restrict the flexibility to attract conclusions utilizing conventional statistical strategies alone.
“This can be a highly effective instance of how digital twins may help unlock insights from small research,” mentioned Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to help smarter, quicker scientific analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering method in direction of attaining symptomatic aid and illness modification in Alzheimer’s. This can help our efforts to advance an optimized second-generation remedy,” mentioned Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins supply a brand new lens for deciphering biomarker traits over time—particularly in early-stage trials the place each knowledge level issues.”
For extra info, go to www.unlearn.ai or observe us on LinkedIn and X/Twitter.
